- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04976166
Shared Decision Making for Choosing renAl Replacement Therapy in Chronic Kidney Disease Patients (SDM-ART)
Shared Decision Making for Choosing renAl Replacement Therapy in Chronic Kidney Disease Patients (SDM-ART Trial)
Shared decision making (SDM) is an approach where clinicians and patients make decisions together using the best available evidence. An understanding of the patient's treatment goals, the advantages and disadvantages of treatment options, and the likelihood of achieving the outcomes are important to patients. International guidelines recommend that all patients with chronic kidney disease (CKD) at pre-dialysis stage should be educated to improve their knowledge and understanding of their condition and to choose the options for renal replacement therapy (RRT).
Despite these recommendations, pre-dialysis educations are often infrequent. Many patients feel unprepared. Wrong or insufficient understanding due to insufficient explanation of treatment can lead to negative emotions. This may lead to a situation in which the patient loses the opportunity to make patient's own choices, resulting in emergency dialysis or dialysis modality that is not suitable for patients. Therefore, this study aims to evaluate whether SDM has an effect on the choice of RRT among CKD patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Sejoong Kim, MD,PhD
- Phone Number: +82-10-9496-4899
- Email: sejoong@snubh.org
Study Locations
-
-
-
Daegu, Korea, Republic of
- Recruiting
- Kyungpook National University Chilgok Hospital
-
Daegu, Korea, Republic of
- Recruiting
- Kyungpook National University Hospital
-
Daejeon, Korea, Republic of
- Recruiting
- Daejeon Eulji Medical Center
-
Goyang, Korea, Republic of
- Recruiting
- Dongguk University Ilsan Hospital
-
Gwangju, Korea, Republic of
- Recruiting
- Chonnam National University Hospital
-
Incheon, Korea, Republic of
- Recruiting
- Gachon University Gil Medical Center
-
Pusan, Korea, Republic of
- Recruiting
- Pusan National University Hospital
-
Seoul, Korea, Republic of
- Recruiting
- Seoul National University Hospital
-
Seoul, Korea, Republic of
- Recruiting
- Severance Hospital
-
Seoul, Korea, Republic of
- Recruiting
- Samsung Medical Center
-
Seoul, Korea, Republic of
- Recruiting
- Korea University Guro Hospital
-
Seoul, Korea, Republic of
- Recruiting
- Seoul National University Boramae Medical Center
-
Seoul, Korea, Republic of
- Recruiting
- Kyung Hee University Hospital at Gangdong
-
Seoul, Korea, Republic of
- Recruiting
- The Catholic University of Korea Seoul St. Mary's Hospital
-
Seoul, Korea, Republic of
- Recruiting
- Ewha Woman's University Seoul Hospital
-
Seoul, Korea, Republic of
- Recruiting
- The Catholic University of Korea Eunpyeong St. Mary's Hospital
-
Ulsan, Korea, Republic of
- Recruiting
- Ulsan University Hospital
-
Wonju, Korea, Republic of
- Recruiting
- Yonsei University Wonju Severance Christian Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 13620
- Recruiting
- Bundang Seoul National University Hospital
-
Contact:
- Sejoong Kim, MD,PhD
- Phone Number: +82-10-94964899
- Email: sejoong2@snu.ac.kr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients with chronic kidney disease whose nephrologist predicts initiation of renal replacement therapy within 12 months:
- Patients with grade 5 of chronic kidney disease [defined as a creatinine-based estimated glomerular filtration rate (eGFR) < 15 ml/dL/1.73m2 at least 2 times at intervals of 2 weeks or longer]
- Patients with the cystatin C-based eGFR < 15 ml/dL/1.73m2 at least once if the creatinine-based eGFR does not accurately evaluate the kidney function of patient due to patient characteristics
- Patients whose nephrologist require renal replacement therapy within 12 months due to the patient's comorbidities even when the eGFR is 15ml/dL/1.73m2 or higher
- Patients aged between 19 and 80 years
- Patients who understand the study
- Patients who have no permanent access device for long-term maintenance dialysis
Exclusion Criteria:
- Patients who have contraindication to perform peritoneal dialysis due to abdominal surgery
- Patients whose life expectancy is less than 6 months due to underlying diseases
- Patients who have enrolled in other clinical trials within 3 months or plan to participate in other clinical trials during this clinical trial period
- Patients judged by the investigator to be inappropriate for participation in this clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Conventional group
Videos and leaflets will be provided.
Patients will have education using leaflets for 5 minutes in each hospital at months 0 and 2, respectively.
|
More informed and detailed education
Shared decision making
education as usual
|
|
Experimental: Extensive Informed Decision Making group
Videos, leaflets, and intensive learning materials will be provided.
Patients in the EIDM group will receive more informed and detailed education than those in the conventional group.
Patients will have education for more than 10 minutes at months 0 and 2, respectively.
|
More informed and detailed education
Shared decision making
education as usual
|
|
Experimental: Shared Decision Making group
Videos, leaflets, and intensive learning materials will be provided.
Patients will check self-assessment items, and then have education according to the patients' preference using a self-developed counseling calendar.
Patients will have education for more than 10 minutes at months 0 and 2, respectively.
|
More informed and detailed education
Shared decision making
education as usual
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The ratio of hemodialysis to non-hemodialysis
Time Frame: 12 months
|
To compare the proportion of hemodialysis versus non-hemodialysis (peritoneal dialysis and kidney transplantation) treatments among the groups
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Economic efficiency using a cost-utility analysis
Time Frame: Month 2, and 12
|
The incremental cost-utility ratio (ICUR) is calculated by the ratio of differences in costs and utilities.
|
Month 2, and 12
|
|
Patients' satisfaction assessed by Patient Satisfaction Questionnaire (ZUF-8)
Time Frame: Month 0, 2, and 12
|
The ZUF-8 is an 8-items questionnaire to assess satisfaction in patients using a scale from 1,"poor" to 4,"excellent".
Originally, ZUF-8 used a 4-point scale, but in this study, the investigators further extended the scoring system of this questionnaire from four to five incremental stages of perceived satisfaction, i.e. "poor (1)," rather good (2)," good (3)," very good (4)," extraordinary (5)".
The minimum value is 8 and the maximum value is 40.
Higher scores mean a better outcome.
|
Month 0, 2, and 12
|
|
Patients' evaluation of the SDM process assessed by Shared Decision-Making Questionnaire (SDM-Q-9)
Time Frame: Month 0, 2, and 12
|
The SDM-Q-9 questionnaire is a nine item measure.
Items are reported with six response options ranging from 0, "completely disagree", to 5, "completely agree".
In this study, six response options were converted into five incremental stages, i.e. "strongly disagree (1)," somewhat disagree (2)," neither disagree nor agree (3)," somewhat agree (4)," strongly agree (5)".
To calculate the total scale score, items are summed resulting in a range from 9-45.
Higher scores reflect a participant's participation in shared decision making regarding their treatment.
|
Month 0, 2, and 12
|
|
Patients' adherence to medication assessed by Morisky 8-item Medication Adherence Scale (MMAS-8)
Time Frame: Month 0, 2, and 12
|
The MMAS-8 is an 8-items questionnaire and the scale included 7 items with yes/no response options and 1 item with a 5-point Likert scale response option.
Cumulative score based on 8 items are used to obtain final adherence score ranging from 0 to 8. Adherence is defined accordingly as low (score 0-5), medium (score 6-7) and high (score 8).
|
Month 0, 2, and 12
|
|
unplanned dialysis
Time Frame: 12 months
|
To compare the rate of unplanned dialysis among the groups
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sejoong Sejoong, MD,PhD, Seoul National University Bundang Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SDMART
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease Stage 5
-
Heinrich-Heine University, DuesseldorfRecruitingVaccine Response Impaired | Chronic Kidney Disease Stage 5 on Dialysis | Chronic Kidney Disease Stage 5 With TransplantGermany
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
University of MichiganTheravance BiopharmaCompletedEnd-Stage Renal Disease | Stage 5 Chronic Kidney DiseaseUnited States
-
National University, SingaporeUnknownChronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4Singapore
-
Zydus Lifesciences LimitedCompletedAnemia | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4India
-
ArdelyxAstraZenecaCompletedEnd Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5United States
-
liberDi Ltd.RecruitingChronic Kidney Disease Stage 5Israel
-
ShireCompletedChronic Kidney Disease, Stage 5United States, Germany, Puerto Rico, United Kingdom
-
Savient PharmaceuticalsCompletedChronic Kidney Disease Stage 5United States
-
Queen Margaret UniversityBritish Kidney Patients AssociationUnknownChronic Kidney Disease Stage 5United Kingdom
Clinical Trials on Education
-
Erzincan UniversityCompletedQuality of Life | Nursing Caries | Breastfeeding | Postpartum | Nursing Model | Levine Conservation Model
-
Oregon Health and Science UniversityEnrolling by invitation
-
Mexican National Institute of Public HealthUniversity of North Carolina, Chapel Hill; Danone ResearchCompleted
-
Simon Fraser UniversityNatural Sciences and Engineering Research Council, CanadaNot yet recruiting
-
University of Social Sciences and Humanities, WarsawNational Science Centre, PolandRecruiting
-
Marmara UniversityCompleted
-
Pamukkale UniversityCompletedBreastfeeding | ImmigrantTurkey
-
University of MostarUnknownPain Score | Apgar Score | Mental Health Issue | Delivery Mode | Breastfeeding RateBosnia and Herzegovina
-
Centro de Endocrinologia Experimental y AplicadaNational Council of Scientific and Technical Research, ArgentinaCompletedType 2 DiabetesArgentina
-
Mclean HospitalCompleted